FIGURE 4. A role for deregulated MITF in melanoma tumorigenesis and survival.
From the following article:
Levi A. Garraway, Hans R. Widlund, Mark A. Rubin, Gad Getz, Aaron J. Berger, Sridhar Ramaswamy, Rameen Beroukhim, Danny A. Milner, Scott R. Granter, Jinyan Du, Charles Lee, Stephan N. Wagner, Cheng Li, Todd R. Golub, David L. Rimm, Matthew L. Meyerson, David E. Fisher and William R. Sellers
Nature 436, 117-122(7 July 2005)
doi:10.1038/nature03664
a, MITF and BRAF(V600E) co-expression confers factor-independent growth in hTERT/CDK4(R24C)/p53DD melanocytes. Absorbance (mean and standard error) following crystal violet staining, and photographs at 3 weeks are shown. b, Extracts from hTERT/CDK4(R24C)/p53DD melanocytes expressing BRAF(V600E) 
HA-MITF were immunoblotted using antibodies against BRAF, MITF, HA-tag or 
-tubulin. p53DD, dominant-negative p53. c, d, Growth of cells expressing BRAF(V600E) HA-MITF in soft agar. Colonies (mean and standard error) and photographs taken at 8 weeks are shown (magnification 40 
). e, Growth of melanoma cell lines expressing empty vector or dominant-negative MITF (dn) at 48 hours relative to uninfected controls. Means and standard deviations are shown; MITF copy number is indicated. f, Cell growth (mean and standard deviation, 72 h) of MALME-3M cells expressing dnMITF compared to uninfected controls, in the presence or absence of docetaxel or cisplatin (*P < 0.05, **P < 0.01).
